Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 4.1.1.11 extracted from

  • Gopal, P.; Tasneen, R.; Yee, M.; Lanoix, J.; Sarathy, J.; Rasic, G.; Li, L.; Dartois, V.; Nuermberger, E.; Dick, T.
    In vivo-selected pyrazinoic acid-resistant Mycobacterium tuberculosis strains harbor missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1 (2017), ACS Infect. Dis., 3, 492-501 .
    View publication on PubMedView publication on EuropePMC

Protein Variants

Protein Variants Comment Organism
A128E naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
A128S naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
C17R naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
D116Y naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
E130G naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
F107L naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
H21N naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
H21Q naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
I115V naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
L131P naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
L136P naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
L136R naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
M117I naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
M117V naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
additional information construction of a panD mutant strain, the panD mutant grows as well as the wild-type in infected mice. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. Location of amino acid sequence polymorphisms in PanD of POA-resistant Mycobacterium tuberculosis strains isolated from POA-treated mice Mycobacterium tuberculosis
N127K naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
V138A naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
V138M naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis

Organism

Organism UniProt Comment Textmining
Mycobacterium tuberculosis
-
-
-

Synonyms

Synonyms Comment Organism
aspartate decarboxylase
-
Mycobacterium tuberculosis
PanD
-
Mycobacterium tuberculosis

General Information

General Information Comment Organism
malfunction an in vivo-selected pyrazinoic acid-resistant Mycobacterium tuberculosis strain harbors a missense mutation in the aspartate decarboxylase PanD. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. POA/PZA resistance-conferring panD mutations are observed in POA-treated mice but not yet among clinical strains isolated from PZA-treated human patients Mycobacterium tuberculosis